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Campylobacter concisus is a bacterium that is associated with inflammatory
bowel disease (IBD). Immunosuppressive drugs including azathioprine (AZA) and
mercaptopurine (MP), and anti-inflammatory drug such as 5-aminosalicylic acid (5-ASA)
are commonly used to treat patients with IBD. This study aimed to examine the effects
of AZA, MP, and 5-ASA on the growth of IBD-associated bacterial species and to
identify bacterial enzymes involved in immunosuppressive drug metabolism. A total of
15 bacterial strains of five species including 11 C. concisus strains, Bacteroides fragilis,
Bacteroides vulgatus, Enterococcus faecalis, and Escherichia coli were examined. The
impact of AZA, MP, and 5-ASA on the growth of these bacterial species was examined
quantitatively using a plate counting method. The presence of enzymes involved in
AZA and MP metabolism in these bacterial species was identified using bioinformatics
tools. AZA and MP significantly inhibited the growth of all 11 C. concisus strains.
C. concisus strains were more sensitive to AZA than MP. 5-ASA showed inhibitory
effects to some C. concisus strains, while it promoted the growth of other C. concisus
strains. AZA and MP also significantly inhibited the growth of B. fragilis and B. vulgatus.
The growth of E. coli was significantly inhibited by 200 µg/ml of AZA as well as 100
and 200 µg/ml of 5-ASA. Bacterial enzymes related to AZA and MP metabolism were
found, which varied in different bacterial species. In conclusion, AZA and MP have
inhibitory effects to IBD-associated C. concisus and other enteric microbes, suggesting
an additional therapeutic mechanism of these drugs in the treatment of IBD. The strain
dependent differential impact of 5-ASA on the growth of C. concisus may also have
clinical implication given that in some cases 5-ASA medications were found to cause
exacerbations of colitis.
Keywords: Campylobacter concisus, inflammatory bowel disease, immunosuppressive drug, azathioprine,
mercaptopurine, anti-inflammatory drug, 5-aminosalicylic acid, enteric bacteria
Liu et al. IBD Drugs Affect C. concisus Growth
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic inflammatory
disease of the gastrointestinal tract with Crohn’s disease (CD) and
ulcerative colitis (UC) being the two major forms. The etiology
of IBD remains elusive but it is believed that multiple factors
such as genetic susceptibility, environmental factor, dysregulated
immune response as well as intestinal microbiota, are involved
in the development of the disease (Sartor and Mazmanian,
2012). Accumulated evidence supports the role of Campylobacter
concisus as the initiator of a subgroup of IBD (Zhang et al., 2014a;
Zhang, 2015).
C. concisus is a Gram-negative spiral shaped motile bacterium
(Tanner et al., 1981). Their growth under anaerobic and
microaerobic conditions is strongly favored by the presence of
H2, and also affected by other environmental factors in the
gastrointestinal tract such as pH and bile (Lee et al., 2014; Ma
et al., 2015). The human oral cavity is the natural reservoir of
C. concisus. However, it may also colonize the intestinal tract of
some individuals and its prevalence in the intestinal tissues has
been associated with IBD (Tanner et al., 1981; Lastovica, 2006;
Zhang et al., 2009, 2010; Mahendran et al., 2011; Mukhopadhya
et al., 2011; Kirk et al., 2016). In addition to IBD, C. concisus
was frequently isolated from diarrheal stool samples, suggesting
its involvement in diarrheal disease (Lindblom et al., 1995;
Lastovica, 2006; Kalischuk and Inglis, 2011; Nielsen et al., 2013).
Some oral C. concisus strains were found to invade human
intestinal epithelial cells, further supporting the idea that they
can cause enteric disease (Nielsen et al., 2011; Ismail et al., 2012,
2013). Various virulence factors were found in C. concisus, such
as the zonula occludens toxin (Zot), which was shown to cause
prolonged damage to the intestinal epithelial barrier, increase and
enhance the response of macrophages to other bacterial species
(Mahendran et al., 2013, 2016; Liu et al., 2016).
The thiopurine drugs azathioprine (AZA) and
mercaptopurine (MP) are immunosuppressive drugs that
are commonly used for induction and maintenance of remission
in patients with IBD (Chande et al., 2015, 2016; Timmer et al.,
2016). AZA is a prodrug ofMP. Once absorbed, AZA is processed
to release MP and a glutathionyl derivative of 1-methyl-4-
nitroimidazole in the liver or other body cells (Hobara and
Watanabe, 1981; Elion, 1993; Gervasio et al., 2000). This process
is due to the action of glutathione, which is in part controlled
by the enzyme glutathione S-transferase (GST) (Eklund et al.,
2006). MP undergoes further enzymatic conversions, leading to
the production of the intermediates thioinosine monophosphate
(TIMP) and thioxanthine monophosphate (TXMP) and the
Abbreviations: 5-ASA, 5-aminosalicylic acid; 6-MMP, 6-methylmercaptopurine;
MP, mercaptopurine; AZA, azathioprine; CD, Crohn’s disease; GMPS,
guanosine monophosphate synthetase; GSH, glutathione; GST, glutathione
S-transferase; HGPRT, hypoxanthine guanine phosphoribosyltransferase; IBD,
inflammatory bowel disease; IMPD, inosine monophosphate dehydrogenase;
MTIMP, methylthioinosine monophosphate; TGDP, thioguanine diphosphate;
TGMP, thioguanine monophosphate; TGNs, thioguanine nucleotides; TGTP,
thioguanine triphosphate; TIMP, thioinosine monophosphate; TPMT, thiopurine
methyltransferase; TXMP, thioxanthine monophosphate; UC, ulcerative colitis;
XO, xanthine oxidase; XDH, xanthine dehydrogenase.
active metabolite thioguanine nucleotides (TNGs). TNGs act as
purine antagonists for DNA polymerase and induce mismatches
in DNA synthesis, thus inhibit proliferation of fast-growing cells
lacking a purine salvage pathway such as B and T lymphocytes
(Nielsen et al., 2001; Sahasranaman et al., 2008).
5-aminosalicylic acid (5-ASA) is an anti-inflammatory drug
in the sulfonamide family that is also commonly used to induce
and maintain remission in IBD (Hanauer, 2006; Nikfar et al.,
2009). The mechanism of action of 5-ASA is believed to be
due to the activation of the peroxisome proliferation-activated
receptor gamma (PPAR-γ) (Ireland and Jewell, 1990). Activation
of PPAR-γ leads to a decreased transcriptional activity of NF-κB
and reduction of inflammatory cytokine production (Dubuquoy
et al., 2003; Rousseaux et al., 2005).
Currently, limited information is available regarding whether
these immunosuppressive and anti-inflammatory drugs used in
IBD therapies have an impact on bacterial species in the human
gastrointestinal tract. To gain this information, in this study we
examined the effects of AZA, MP and 5-ASA on the growth of C.
concisus and the four other enteric bacterial species. This study
found that AZA and MP inhibited the growth of IBD-associated
bacterium C. concisus and some other enteric bacterial species.
AZA showed a greater bacterial inhibitory effect to C. concisus
thanMP. 5-ASA had differential effects on the growth of different
C. concisus strains. The clinical implications of these findings and
the potential therapeutic mechanisms of the bacterial inhibitory
effects of the examined drugs were discussed.
MATERIALS AND METHODS
Bacterial Species Included in This Study
A total of 15 bacterial strains of five species were used in this
study, including 11 C. concisus strains and Bacteroides fragilis
ATCC 25285, Bacteroides vulgatus ATCC 8482, Enterococcus
faecalis ATCC 19433 and Escherichia coli K12 (Bachmann, 1972;
Gregory et al., 1978; Moschetti et al., 1998). Of the 11 C. concisus
strains examined, three strains were from patients with CD,
four strains from patients with UC, one strain from patient
with gastroenteritis and three strains from healthy controls.
These 11 C. concisus strains were randomly chosen from C.
concisus strains isolated in our previous studies (Zhang et al.,
2009, 2010; Mahendran et al., 2011). C. concisus consists of two
genomospecies (GS), among the 11 strains included, five strains
were from GS1 and six strains were from GS2 (Mahendran
et al., 2015; Chung et al., 2016). The other bacterial strains were
purchased from the American Type Culture Collection (VA,
USA). Detailed information of bacterial species and strains used
in this study were provided in Table 1.
Effects of AZA, MP, and 5-ASA on
C. concisus Growth
Four concentrations of drugs were examined for their effects on
bacterial growth, which were 10, 50, 100, and 200 µg/ml. These
concentrations were estimated based on the doses of AZA and
MP used in the treatment of IBD. The doses used in the treatment
of IBD were 2.5mg per kilogram of body weight per day for
AZA and 1.5mg per kilogram of body weight per day for MP
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TABLE 1 | Bacterial strains used in this study.
Strain ID Health
status
Isolation
source
Genomospecies
P2CDO4 CD Saliva GS2
P11CDO-S1 CD Saliva GS2
P20CDO-S2 CD Saliva GS2
P14UCO-S1 UC Saliva GS2
P3UCO1 UC Saliva GS1
P3UCLW1 UC Feces GS1
P3UCB1 UC Intestinal biopsy GS1
13826 Gastroenteritis Feces GS2
H14O-S1 Healthy Saliva GS2
H12O-S1 Healthy Saliva GS1
H17O-S1 Healthy Saliva GS1
B. fragilis ATCC 25285 Appendix
abscess
Appendix
abscess
B. vulgatus ATCC 8482 NA Feces
E. faecalis ATCC 19433 NA NA
E. coli K12 Convalescent
diphtheria
Feces
GS1, genomospecies 1; GS2, genomospecies 2; The 11 C. concisus strains are
underlined; and their GS was examined in our previous studies (Mahendran et al., 2015;
Chung et al., 2016). Letters P and H in strain ID indicate strains isolated from patients
with inflammatory bowel disease and healthy controls respectively. O indicates oral strains
isolated from saliva samples; B indicates a strain isolated from intestinal biopsy; and LW
indicates a strain isolated from fecal sample. CD, Crohn’s disease; UC, ulcerative colitis;
NA, information not available.
(Pearson et al., 1995). Given this, the concentrations of AZA and
MP entering into the intestinal tract would be 100–200 µg/ml,
assuming the body weights are 60–70 kilograms and the volume
in the stomach is 1 liter (Sherwood, 2015). The doses of 5-ASA
used in the treatment of IBD vary greatly depending on different
clinical situations (Wang et al., 2016). The drug concentrations
examined in this study were not intended to accurately reflect
the concentrations of these drugs in the human intestinal tract,
which was impossible to do. All test drugs were purchased from
Sigma-Aldrich (Castle Hill, Australia).
C. concisus strains were cultured on horse blood agar (HBA)
plates under anaerobic conditions supplemented with 5% H2 for
48 h at 37◦C as previously described (Lee et al., 2014). Bacteria
of each C. concisus strain were then collected from the plate and
diluted to OD600 of 0.025 with PBS. An aliquot of bacteria (5
µl) was spread in radial pattern on the agar plates containing
different concentrations of AZA, MP or 5-ASA (10, 50, 100, and
200 µg/ml). Plates were then incubated for 48 h. Each treatment
was performed in triplicate. Following incubation, bacteria were
collected from each plate with 1 ml PBS, from which seven serial
dilutions (10−1–10−7) were prepared. An aliquot (5 µl) of each
of the seven dilutions as well as the undiluted original inoculum
was then dropped onto HBA plates in quadruplicate. The plates
were incubated for 48 h and the colony forming unit (CFU) was
determined.
B. fragilis, B. vulgatus, E. faecalis and E. coli were cultured
on HBA plates for 24 h at 37◦C under anaerobic conditions
supplemented with 5% H2 (Whelan and Hale, 1973; Ruoff et al.,
1990; Likotrafiti et al., 2016). Following initial cultivation, the
effects of AZA, MP and 5-ASA on the growth of B. fragilis, B.
vulgatus, E. faecalis and E. coli were examined under the same
cultivation conditions as those used for C. concisus except the
cultivation period was 24 h instead of 48 h giving the rapid
growth of these bacterial species (Whelan and Hale, 1973; Ruoff
et al., 1990; Likotrafiti et al., 2016).
The growth of bacterial strains on HBA plates containing
different concentrations of AZA, MP, or 5-ASA was expressed as
the percentage of the CFU relative to the CFU of the negative
control of the same strain. Experiments were repeated three
times.
The Controls
AZA and MP were dissolved in dimethyl sulfoxide (DMSO) at a
stock concentration of 100 mg/ml. The concentration of DMSO
was adjusted to 0.2% for all concentrations of AZA and MP.
Bacterial strains cultured on plates containing DMSO at 0.2%
were therefore used as the negative controls for AZA and MP. 5-
ASA was dissolved in water at a stock concentration of 1 mg/ml.
Bacterial strains cultured on plates without any drugs were
served as the negative controls for 5-ASA. Tetracycline at final
concentration of 0.5 µg/ml was used as antibiotic control for C.
concisus, with representative strain 13826 being used (Aabenhus
et al., 2005).
Examination of the Presence of Enzymes
Required for AZA and MP Metabolism in
Different Bacterial Species Using
Bioinformatics Tools
The enzymes involved in AZA and MP metabolism include
GST, HGPRT, inosine monophosphate dehydrogenase (IMPD),
GMPS, xanthine oxidase (XO), and TPMT. The presence
of these enzymes in the bacterial species examined in this
study was identified by searching the bacterial genomes for
proteins annotated with the same enzyme names, as well as
proteins containing the same enzyme domains. Two protein
databases were used including National Center for Biotechnology
Information (NCBI) protein database and Universal Protein
Resource (UniProt; Apweiler et al., 2004; Pruitt et al.,
2007).
Of the 11C. concisus strains included, seven of them have been
previously sequenced by our group, the presence of the enzymes
were examined in these seven strains as well as the publically
available genome of C. concisus strain 13826 (accession number
CP000792.1; Chung et al., 2016).
Statistical Analysis
Student’s t–tests (unpaired, two tailed) were used to compare
the CFU of bacterial strains in response to AZA, MP and
5-ASA with those of the negative controls. P < 0.05 were
considered as statistically significant. Statistical analyses
were performed using GraphPad Prism version 6 (San
Diego, CA). Data were shown as the mean ± SD from
triplicates.
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RESULTS
Effects of AZA, MP, and 5-ASA on the
Growth of C. concisus Strains
AZA inhibited the growth of all 11 C. concisus strains examined
(Figure 1, Table 2). The CFU of eight strains grown on plates
containing 10 µg/ml of AZA were significantly lower as
compared to that grown on the negative control plates (P< 0.05).
On plates containing concentrations of 50, 100, or 200µg/ml
of AZA, the CFU of all 11 strains were significantly reduced
as compared to their respective strains grown on HBA plates
without drugs (negative controls; P< 0.05). C. concisus appeared
to be very sensitive to AZA. In the presence of 10 µg/ml of
AZA, more than half of the strains (6/11, 55%) had over 80% of
CFU reduction as compared to their respective negative controls.
In the presence of 50µg/ml of AZA, all strains except for one
isolated from intestinal biopsies of a patient with UC (P3UCB1)
had over 98% CFU reduction as compared to their negative
controls. In the presence of 100µg/ml of AZA, all strains had
more than 99% CFU reduction, and one strain showed complete
inhibition of growth in which no colonies were observed. Seven
strains showed complete inhibition of growth when 200µg/ml of
AZA was present.
The growth of the 11 C. concisus strains was also inhibited
by MP (Figure 1, Table 2). When the C. concisus strains were
grown on HBA plates containing 10 µg/ml of MP, the growth
of six strains was significantly reduced as compared with their
respective negative controls (P < 0.05). At concentrations of 50,
100, and 200 µg/ml, MP significantly inhibited the growth of all
11 strains as compared with their negative controls (P< 0.05). In
contrast to what was observed with AZA, MP at concentration of
200 µg/ml did not completely abolish the growth of C. concisus;
bacterial colonies were still observed in all strains.
The effects of 5-ASA on C. concisus growth varied between
strains (Figure 1, Table 2). Among the 11 strains examined, the
growth of five strains (13826, P3UCO1, P3UCLW1, P3UCB1,
andH17O-S1) was significantly inhibited by 5-ASA (P< 0.05). In
contrast, 5-ASA at concentrations of 50, 100, and 200µg/ml (P<
0.05) significantly enhanced the growth of twoC. concisus strains,
P2CDO4 andH12O-S1. The growth of the remaining four strains
did not change significantly in the presence of 5-ASA.
The positive control antibiotic tetracycline hadmore than 99%
of inhibitory effect on the growth of C. concisus strain 13826 at
concentration of 0.5 µg/ml.
Effects of AZA, MP, and 5-ASA on the
Growth of B. fragilis, B. vulgatus,
E. faecalis, and E. coli
B. fragilis and B. vulgatus tended to have similar susceptibility
toward AZA; their growth was significantly inhibited by AZA
at the concentrations of 10 and 50 µg/ml (P < 0.05) and
completely abolished at higher concentrations (100 and 200
µg/ml; Figure 2, Table 2). The growth of B. fragilis and B.
vulgatus was also significantly inhibited by MP (P < 0.05). B.
fragilis was more sensitive to MP as compared to B. vulgatus;
a significant reduction of growth of B. fragilis was seen in the
presence of 50, 100, and 200 µg/ml of MP while a significant
reduction of growth of B. vulgatus was seen in the presence of
100 and 200 µg/ml of MP (Figure 2, Table 2). 5-ASA did not
significantly affect the growth of B. fragilis and B. vulgatus.
AZA, MP, and 5-ASA did not significantly affect the growth of
E. faecalis.
The growth of E. coli was significantly inhibited by AZA but
only at the highest concentration (200 µg/ml; P < 0.001), while
no inhibitory effect was observed from MP. 5-ASA at 100, and
200 µg/ml significantly reduced the growth of E. coli (P < 0.001;
Figure 2, Table 2).
Comparison of the Bacterial Inhibitory
Effects of AZA and MP
The effects of AZA and MP on inhibiting bacterial growth were
compared between the growth reduction resulted from the same
concentrations of these two drugs and the results were shown in
Figure 3, Table 2.
AZA was more effective than MP in inhibiting bacterial
growth. Six of the 11 C. concisus strains showed significantly
lower growth (P2CDO4, P20CDO-S2, 13826, P14UCO-S1,
P3UCO1, and H12O-S1) in the presence of 10 µg/ml of AZA
as compared with that of the same concentration of MP (P <
0.05; Figure 3, Table 2). This trend was more obvious at higher
concentrations (50, 100 and 200 µg/ml) in which all 11 C.
concisus strains in the presence of AZA had significantly lower
growth as compared to that of the same strains cultured on the
same concentrations of MP (P < 0.01; Figure 3, Table 2).
This trend was also seen in other bacterial species including
B. fragilis, B. vulgatus and E. coli. The growth of B. fragilis and
B. vulgatus was significantly lower in the presence of AZA at
concentrations of 50, 100, and 200 µg/ml as compared to that
of MP at the same concentrations (P < 0.001; Table 2). AZA
significantly decreased the growth of E. coli at concentration of
200 µg/ml, whilst MP did not have significant effects on E. coli
growth (Table 2).
Enzymes Required for AZA and MP
Metabolism in the Bacterial Species
The production of the active metabolites TGNs to inhibit
immune cell DNA synthesis by AZA requires a number of
enzymes (Figure 4). The presence of these enzymes in the
bacterial species and strains included in this study was examined
using publically available protein databases annotated from
sequenced bacterial genomes. Except for the genome of E. faecalis
ATCC 19433, the genomes of the four other bacterial species and
strains examined were fully sequenced without gaps.
The enzyme GST which facilitates the conversion from AZA
to MP, and HGPRT which is required for the formation of the
active metabolite TGNs were not found in C. concisus strains
(Figure 4). In the absence of GST, lessMP is produced fromAZA;
and without HGPRT, conversion of AZA and MP into the active
metabolite TGNs is not possible.
GST was not found in B. fragilis ATCC 25285 and E. faecalis
ATCC 19433, however HGPRT, IMPD, and GMPS were found.
B. vulgatus ATCC 8482 and E. coli K12 strains contained all
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FIGURE 1 | Effects of AZA, MP, and 5-ASA on the growth of C. concisus strains. The growth of C. concisus strains on horse blood agar plates containing
different concentrations of AZA, MP or 5-ASA was expressed as the percentage of the colony forming unit (CFU) relative to the CFU of their respective negative
control. The negative controls were the same C. concisus strains grown on HBA plates without drugs. Strains isolated from patients with CD, UC, gastroenteritis and
healthy controls are colored in blue, red, brown and green respectively. *Indicates statistically significance (*P < 0.05, **P < 0.01, ***P < 0.001). # Indicates complete
inhibition of growth. CD, Crohn’s disease; UC, ulcerative colitis.
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FIGURE 2 | Effects of AZA, MP, and 5-ASA on the growth of B. fragilis, B. vulgatus, E. faecalis, and E. coli. The growth of B. fragilis, B. vulgatus, E. faecalis
and E. coli was expressed as the percentage of the colony forming unit (CFU) relative to the CFU of their respective negative control. The negative controls were the
same bacterial strains grown on horse blood agar plates without drugs. *Indicates statistically significance (*P < 0.05, **P < 0.01, ***P < 0.001). # Indicates complete
inhibition of growth.
the enzymes required for the metabolisms of AZA to TGNs
(Figure 4).
Enzymes TPMT and XO divert the metabolism pathway from
TGNs production. TPMT was absent in all bacterial species and
strains examined and XO was only found in E. coli K12.
DISCUSSION
In this study, we examined the effects of AZA, MP, and 5-
ASA on the growth of IBD associated bacterium C. concisus and
four other enteric bacterial species. We have also examined the
presence of enzymes involving in AZA and MP metabolisms in
these bacterial species.
We found that both AZA and MP significantly inhibited the
growth of C. concisus, a bacterium that was previously found to
be associated with IBD (Figure 1, Table 2). The improvement
of clinical conditions in IBD patients following the treatment
with AZA and MP was believed to be due to the effects
of these drugs on reduction of lymphocyte proliferation and
proinflammatory cytokines (Derijks et al., 2006). Our finding
that AZA and MP have inhibitory effects to C. concisus suggests
that inhibition or elimination of IBD-causing bacterial species
may be an additional therapeutic mechanism contributing to
the beneficial effects of AZA and MP in the treatment of
IBD. This is supported by previous studies showing AZA
and MP also inhibited the growth of Mycobacterium avium
subsp. paratuberculosis, another bacterium that is associated with
human CD (Sanderson et al., 1992; Collins et al., 2000; Sieswerda
and Bannatyne, 2006; Greenstein et al., 2007; Shin and Collins,
2008).
AZA showed a significantly higher potency in inhibiting the
growth of C. concisus as compared to the same concentrations of
MP (Figure 3). In their use as immunomodulatory medications,
AZA is the prodrug of MP. Both AZA and MP are eventually
metabolized to purine analogs that interfere with DNA synthesis
in immune cells (Nielsen et al., 2001). C. concisus does not
possess GST, suggesting that the conversion from AZA to MP
by C. concisus was mainly through the non-enzymatic action.
The enzyme GST does not appear to be a critical enzyme in
determination of bacterial sensitivity to AZA. For example, GST
was not found in C. concisus, B. fragilis and E. faecalis, however
AZA had significant inhibitory effects only to C. concisus and
B. fragilis, not E. faecalis. HGPRT enzyme was not found in
C. concisus, suggesting that most of AZA and MP were not
metabolized to purine analogs by C. concisus. The more effective
inhibitory effects of AZA to C. concisus as compared to MP
would therefore have to come from AZA itself. This view is
further supported by the findings that E. faecalis has all enzymes
required for converting MP to purine analogs, and that AZA and
MP did not significantly affect its growth (Figures 2, 4, Table 2).
Nevertheless, the absence or presence of bacterial enzymes in this
study was identified using bioinformatics analysis, which requires
experimental verification. AZA contains an imidazole ring that is
present in many antifungal agents, which may have contributed
to the better antibacterial properties of AZA as compared to MP
observed in this study (Zhang et al., 2014b).
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FIGURE 3 | Comparison of the inhibitory effect of AZA and MP on C.
concisus growth. C. concisus strains were more sensitive to AZA than MP.
Six of the 11 C. concisus strains (P2CDO4, P20CDO-S2, 13826, P3UCO1,
P14UCO-S1, and H12O-S1) exhibited significantly reduced growth in the
presence of 10 µg/ml of AZA as compared to that of the same concentration
of MP (P < 0.05). When AZA and MP were present at higher concentrations
(50, 100, and 200 µg/ml), the growth of all 11 C. concisus strains were
significantly lower in response to AZA than the same concentrations of MP
(P < 0.01).
When taken orally, about 88%AZA and 50%MP are absorbed
in the gastrointestinal tract (Cuffari et al., 2000). These absorption
rates are affected by both host factors and the mode of drug
delivery (Van Os et al., 1996; Tremaine, 1997). Thus, in patients
with IBD receiving AZA and MP treatment, the concentrations
of these drugs in their gastrointestinal tract vary. Furthermore,
C. concisus strains have various abilities in resistance to AZA,
as judged by the CFU reduction of different strains in the
presence of the same concentrations of AZA (Figure 1, Table 2).
Clinically, AZA and MP are not effective in all patients and some
patients may relapse even under the treatment of AZA and MP.
One possible reason contributing to AZA and MP treatment
failure may be that the IBD-associated bacterial species such as
C. concisus have not been successfully inhibited in these patients
by these drugs. Future studies should be conducted in patients
with IBD to further investigate this issue.
Another interesting finding from this study was that 5-ASA
had different effects on the growth of different C. concisus strains.
While this drug inhibited the growth of some C. concisus strains,
it increased the growth of the other strains (Figure 1, Table 2).
Although 5-ASA is often used in the treatment of IBD, in some
cases 5-ASA medications were found to cause exacerbations
of colitis (Schwartz et al., 1982). Our finding that 5-ASA
promoted the growth of some C. concisus strains suggests that the
deteriorated clinical conditions in patients with IBD caused by 5-
ASA may be due to its effects in increasing the growth of some
IBD causing bacterial species in the intestinal tract. In addition
to its anti-inflammatory effects through reducing the level of
NF-κB, 5-ASA was previously found to inhibit DNA synthesis
in human lymphocytes (Elitsur et al., 1989; Ireland and Jewell,
1990). It is possible that 5-ASA has inhibited the growth of some
C. concisus strains through affecting bacterial DNA synthesis. It is
unclear why some C. concisus strains showed increased growth in
response to 5-ASA. Future studies examining the whole genomes
ofC. concisus strains that had differential responses to 5-ASAmay
provide further information.
In addition to C. concisus, we examined the effects of AZA,
MP, and 5-ASA on the growth of another four enteric bacterial
species. We found that both AZA and MP inhibited the growth
of B. fragilis and B. vulgatus. B. fragilis colonizes the human
intestinal tract and accounts for 0.5% of the commensal human
colonic flora, but also causes various human infections (Wexler,
2007). The enterotoxigenic B. fragilis strain has been implicated
in IBD (Prindiville et al., 2000). B. vulgatus and E. faecalis were
shown to induce colitis in animal models of IBD (Onderdonk
et al., 1981; Balish and Warner, 2002). Our findings that AZA
and MP have inhibitory effects toward C. concisus and other
IBD-associated bacterial species suggest that it may be possible
to develop non-absorbable forms of AZA or MP to inhibit
IBD-associated Campylobacter species and Bacteroides species
in the gastrointestinal tract, which can be used as a strategy
for long-term IBD treatment with reduced toxicity to the hosts.
Low concentration of AZA (10 ug/ml) showed a much greater
inhibition to C. concisus than other bacterial species, suggesting
the possibility of using low concentration of non-absorbable
forms of AZA to treat a subgroup of IBD initiated by C.
concisus without disturbing the balance of microbiota of the
gastrointestinal tract.
The findings from this study and previous studies that AZA,
MP, and 5-ASA had different effects on the growth of multiple
bacterial species residing the human gastrointestinal tract suggest
that these drugs may influence gut microbiota in general. The
changed microbiota caused by these drugs may further affect the
mucosal immunity or colonization of opportunistic pathogens in
the gastrointestinal tract of patients with IBD.
The data presented in this study were from laboratory culture
of individual bacterial species. Despite their strong potential
clinical implications, direct examination of the effects of these
immunosuppressive and anti-inflammatory drugs on the growth
of bacterial species in the human gastrointestinal tract should
be conducted using saliva, biopsy and fecal samples collected
from patients with IBD prior to and following treatment, which
will provide information regarding the effects of these drugs on
the bacterial species community in the human gastrointestinal
tract.
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FIGURE 4 | Identification of enzymes required for AZA and MP metabolism in C. concisus and other four enteric bacterial species. (A) The process of
generating TGNs from AZA and MP. This part of the information was obtained from previous publications (Eklund et al., 2006; Meggitt et al., 2011). TGNs are purine
analogs that inhibit DNA synthesis in immune cells which is the therapeutic mechanism of AZA and MP. GSH, glutathione; GS-imidazole, glutathionyl derivative of
1-methyl-4-nitroimidazole; GST, glutathione S-transferase; TPMT, thiopurine methyltransferase; 6-MMP, 6-methylmercaptopurine; HGPRT, hypoxanthine guanine
phosphoribosyl transferase; XO, xanthine oxidase; TIMP, thioinosine monophosphate; MTIMP, methylthioinosine monophosphate; IMPD, inosine monophosphate
dehydrogenase; TXMP, thioxanthine monophosphate; GMPS, guanosine monophosphate synthetase; TGNs, thioguanine nucleotides; TGMP, thioguanine
monophosphate; TGDP, thioguanine diphosphate; TGTP, thioguanine triphosphate. (B) The presence of enzymes required for AZA and MP metabolism in C. concisus
and other bacterial species. This part of the information was obtained in this study by bioinformatics analysis. N, not present. Protein IDs listed are NCBI locus (#) or
Uniprot protein ID (*).
CONCLUSIONS
In summary, this study found that clinically used
immunomodulating drugs AZA and MP in the treatment
of IBD inhibited the growth of IBD-associated Campylobacter
species C. concisus, suggesting an additional therapeutic
mechanism of these medications in treatment of IBD. The
anti-inflammatory drug 5-ASA may inhibit or promote the
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growth of C. concisus, depending on the properties of the
strains, whether this is related to 5-ASA induced deteriorating
clinical conditions occurring in some patients with IBD
requires further investigation. Furthermore, this study found
that AZA, MP, and 5-ASA also inhibit the growth of other
enteric bacterial species such as B. fragilis, B. vulgatus, and
E. coli; however, higher concentrations of these drugs are
required.
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